Selective local inhibition of tnfr1-mediated functions at the site of antigen/allergen presentation
AssigneesPLS-Design GmbH, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH), Klinikum rechts der Isar der Technischen Universitaet Muenchen
InventorsReinhard Bredehorst, Thomas Grunwald, Markus Ollert, Carsten Schmidt-Weber, Edzard Spillner
Life of this patent
Estimating the term…
Abstract
The invention relates to a pharmaceutical composition for the modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of TNFR1-mediated functions and of at least one antigen or allergen.
Claims13
A pharmaceutical composition for modulation of T cell and B cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of tumor necrosis factor receptor 1 (TNFR1)-mediated functions and at least one antigen or allergen.
Dependencies are inferred from the claim text.